ES2105923B1 - Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). - Google Patents

Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).

Info

Publication number
ES2105923B1
ES2105923B1 ES09300698A ES9300698A ES2105923B1 ES 2105923 B1 ES2105923 B1 ES 2105923B1 ES 09300698 A ES09300698 A ES 09300698A ES 9300698 A ES9300698 A ES 9300698A ES 2105923 B1 ES2105923 B1 ES 2105923B1
Authority
ES
Spain
Prior art keywords
fiau
metabolite
compositions
hbv
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09300698A
Other languages
English (en)
Other versions
ES2105923A1 (es
Inventor
Dennis W Adair
Kenneth A Smiles
Dannie King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oclassen Pharmaceuticals Inc
Original Assignee
Oclassen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharmaceuticals Inc filed Critical Oclassen Pharmaceuticals Inc
Publication of ES2105923A1 publication Critical patent/ES2105923A1/es
Application granted granted Critical
Publication of ES2105923B1 publication Critical patent/ES2105923B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICIONES PARA EL TRATAMIENTO DE UNA INFECCION Y UNA ENFERMEDAD CAUSADAS POR EL VIRUS DE LA HEPATITIS B (HBV). COMPRENDEN 1-(2 -DESOXI-2-FLUORO-BE-D-ARABINOFURANOSIL)-5-YODOURACILO (FIAU) DE FORMULA FORMULA UN PROFARMACO DE FIAU O UN METABOLITO DE FIAU, EN CANTIDAD SUFICIENTE PARA PROPORCIONAR UNA DOSIS BAJA, PERO ANTIVIRICAMENTE EFICAZ DE FIAU, SU PROFARMACO O METABOLITO, COMPRENDIDA EN EL INTERVALO DE 0,05 A 1 MG/KG-DIA, Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. ESTAS COMPOSICIONES SE PREPARAN MEZCLANDO EL VEHICULO CON EL COMPUESTO FIAU, SU PROFARMACO O METABOLITO PARA PROPORCIONAR DICHA DOSIS BAJA, ASI COMO UNA CONCENTRACION MAXIMA DE FIAU, SU PROFARMACO O METABOLITO EN PLASMA COMPRENDIDA EN EL INTERVALO DE 0,1 A 1, MIG/ML O UNA CANTIDAD DE 0,25, 0,5, 1, 5 O 10 MG DE FIAU, SU PROFARMACO O METABOLITO EN LA COMPOSICION OBTENIDA.
ES09300698A 1992-04-06 1993-04-05 Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). Expired - Lifetime ES2105923B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (2)

Publication Number Publication Date
ES2105923A1 ES2105923A1 (es) 1997-10-16
ES2105923B1 true ES2105923B1 (es) 1998-07-01

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09300698A Expired - Lifetime ES2105923B1 (es) 1992-04-06 1993-04-05 Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).

Country Status (26)

Country Link
US (1) US5432165A (es)
EP (1) EP0565412A1 (es)
JP (1) JPH069403A (es)
CN (1) CN1081879A (es)
AP (1) AP372A (es)
AU (1) AU662804B2 (es)
BE (1) BE1009181A5 (es)
BR (1) BR9306207A (es)
CA (1) CA2092356A1 (es)
EE (1) EE9400068A (es)
ES (1) ES2105923B1 (es)
FR (1) FR2689398B1 (es)
GR (1) GR930100111A (es)
IL (1) IL105169A0 (es)
IT (1) IT1264332B1 (es)
LV (1) LV10191B (es)
MD (1) MD940152A (es)
MX (1) MX9301922A (es)
NO (1) NO931246L (es)
NZ (1) NZ247188A (es)
OA (1) OA10102A (es)
PH (1) PH31116A (es)
PT (1) PT101238A (es)
SI (1) SI9300144A (es)
WO (1) WO1993019762A1 (es)
YU (1) YU23993A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (es) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
BR9306207A (pt) 1998-06-23
BE1009181A5 (fr) 1996-12-03
AU3530293A (en) 1993-10-07
EE9400068A (et) 1995-12-15
MD940152A (ro) 1995-12-31
AP9300513A0 (en) 1993-04-30
YU23993A (sh) 1997-05-28
AP372A (en) 1994-11-24
LV10191A (lv) 1994-10-20
ITTO930226A1 (it) 1994-10-05
EP0565412A1 (en) 1993-10-13
CN1081879A (zh) 1994-02-16
ES2105923A1 (es) 1997-10-16
IL105169A0 (en) 1993-07-08
SI9300144A (en) 1994-03-31
FR2689398B1 (fr) 1994-11-18
WO1993019762A1 (en) 1993-10-14
JPH069403A (ja) 1994-01-18
OA10102A (en) 1996-12-18
CA2092356A1 (en) 1993-10-07
FR2689398A1 (fr) 1993-10-08
PH31116A (en) 1998-02-28
IT1264332B1 (it) 1996-09-23
ITTO930226A0 (it) 1993-04-05
NO931246L (no) 1993-10-07
MX9301922A (es) 1993-10-01
PT101238A (pt) 1994-03-31
GR930100111A (el) 1993-12-30
NO931246D0 (no) 1993-03-31
LV10191B (en) 1995-04-20
US5432165A (en) 1995-07-11
NZ247188A (en) 1995-05-26
AU662804B2 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
IL159087A0 (en) Bridged bicyclic compounds and pharmaceutical compositions containing the same
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
DE69425574D1 (en) L-2',3'-dideoxy-nukleosidanaloga als anti-hepatitis b-(hbv) und anti-hiv-wirkstoffe
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0009485A (pt) Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase
YU2703A (sh) Bistar vodeni anestetski preparat
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
DE69221252D1 (de) Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
TW340115B (en) Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis
ATE14076T1 (de) Galenische zubereitung.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
KR910700054A (ko) B형 간염 비루스 감염의 예방 및 치료를 위한 방법 및 조성물
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
MX9302832A (es) Nuevo medicamento para el tratamiento de la arritmia.